
    
      OBJECTIVES: I. Compare the activity and toxicity of epirubicin and cyclophosphamide with that
      of epirubicin and paclitaxel in patients with metastatic breast cancer.

      OUTLINE: Patients are randomized to receive either epirubicin and cyclophosphamide or
      epirubicin and paclitaxel. Each drug combination is given every 3 weeks for 6 courses in the
      absence of disease progression or unacceptable toxicity.

      PROJECTED ACCRUAL: A total of 704 patients will be accrued for this study.
    
  